Twelve Years Later: How Vaccination Changed the Cervical Cancer Landscape in Brazil

Cervical cancer is a disease that begins with a silent, persistent infection. A tiny virus, invisible to the naked eye, can settle in the cells of the cervix and, over many years, cause those cells to change. These changes start as minor abnormalities, which doctors can spot under a microscope, and if left unchecked, they can grow into serious disease. For decades, the primary defense against this progression was a screening test, a routine check to find these early warning signs before they became dangerous. However, science eventually offered a different kind of shield: a vaccine. By teaching the immune system to recognize and fight the virus before it ever takes hold, this vaccine aims to stop the disease at its source. The question for public health officials has been whether this prevention strategy works on a large scale, transforming the health of entire populations rather than just individuals.

Twelve years after Brazil introduced a national program to vaccinate young people against this virus, researchers have looked at the data to see what has changed. They focused on a specific group of women aged twenty to twenty-four. In 2019, this group represented a generation that had not yet been offered the vaccine. By 2025, the same age group consisted of women who had grown up with the vaccine available to them during their adolescence. The researchers compared the health records of these two groups to see if the presence of the vaccine made a difference in the number of abnormal cell changes and cancers found.

The results show a clear and significant shift. When looking at the routine screening tests performed on women in this age group, the rate of abnormal results dropped noticeably. In 2019, there were roughly 1,672 abnormal findings for every 100,000 women tested. By 2025, that number had fallen to about 1,452 per 100,000. This decline was not uniform across the country; it was most pronounced in the southern and southeastern regions, where the reduction was sharpest. In the north and northeast, the drop was smaller but still present, while the central-west region showed a change that was too small to be certain.

The story becomes even more striking when looking at the most serious outcomes. The researchers examined the records of women who had biopsies, which are tests that confirm whether abnormal cells have developed into pre-cancerous or cancerous growths. In 2019, there were 26 confirmed cases of invasive cancer in this young age group. By 2025, that number had plummeted to just two. On a national level, this represents a reduction of 96 percent. In many specific regions, the number of cases fell so low that it appeared to have vanished entirely within the data for that year. Similarly, the rate of high-grade pre-cancerous lesions, which are the immediate precursors to cancer, dropped from an incidence of 11.89 per 100,000 women in 2019 to 4.51 per 100,000 in 2025.

The authors of the study are careful to note that these numbers tell a story of population-level trends rather than individual medical histories. They point out that the sharp decline in cancer cases is based on very small absolute numbers, which requires cautious interpretation. Furthermore, the drop in abnormal screening results might be partly influenced by changes in how often women in this age group get tested, as they are technically outside the standard age range for routine screening in Brazil. Despite these limitations, the convergence of data—fewer abnormal cells, fewer pre-cancerous growths, and a dramatic drop in cancer cases—strongly suggests that the vaccination program is working as intended. The findings indicate that the vaccine is successfully interrupting the chain of infection and disease in the youngest generations, offering a glimpse of a future where this cancer becomes a rarity rather than a common threat.